Real-World Data & Evidence

Advanced search

Chinese experience on using RWE to support drug research, development and evaluation


The article describes the regulatory approaches to the collection, analysis and usage of real-world data applied in China.

About the Authors

A. S. Kolbin
FSBEI HE I.P. Pavlov SPbSMU MOH Russia
Russian Federation

Competing Interests:

St. Petersburg

D. Yu. Belousov
LLC “Center for Pharmacoeconomics Research”
Russian Federation


Competing Interests:

Авторы декларируют отсутствие конфликта интересов.


1. Sun YX, Wei FF, Yang Y. Opportunities and Challenges in Using Real-World Evidence to Support Regulatory Decision Making for Drug and Medical Devices. Chinese Journal of Pharmacovigilance. 2017;(06):353–8.

2. Wu YL, Chen XY, Yang ZM, et al (Wu Jieping Medical Foundation, Chinese Thoracic Oncology Group). Guidance on Real World Research. 2018.

3. General Office of the CPC Central Committee, General Office of the State Council. Opinions on Deepening the Evaluation, Review and Approval System Reform and Encouraging Innovation of Drugs and Medical Devices. 2017.

4. ADAPTABLE Investigators. Aspirin Dosing: a Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study protocol. Published June, 2015, 5.

5. Berger M, Daniel G, Frank K, et al. A frame work for regulatory use of real-world evidence. White paper prepared by the Duke Margolis Center for Health Policy. 2017, 6.

6. Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clinical pharmacology and therapeutics. 2019;106(1):36.

7. Dreyer NA. Advancing a framework for regulatory use of real-world evidence: when real is reliable. Therapeutic innovation & regulatory science. 2018;52(3):362–8.

8. Egger M, Moons KGM, Fletcher C, et al. GetReal: from efficacy in clinical trials to relative effectiveness in the real world. Research synthesis methods. 2016;7(3):278–81.

9. Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454–63.

10. Institute of Medicine 2009. Initial national priorities for comparative effectiveness research. Washington, DC: The National Academies Press.

11. James S. Importance of post-approval real-word evidence. European Heart Journal-Cardiovascular Pharmacotherapy. 2018;4(1):10–11.

12. Kohl S. Joint HMA/EMA task force on big data established. Eur J Hosp Pharm. 2017;24(3): 180–90.

13. Lash TL, Fox MP, Fink AK. Applying quantitative bias analysis to epidemiologic data[M]. Springer Science & Business Media, 2011.

14. Makady A, de Boer A, Hillege H, et al. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value in health. 2017;20(7):858–65.

15. Olariu E, Papageorgakopoulou C, Bovens SM, et al. Real world evidence in Europe: a snapshot of its current status. Value in Health. 2016;19(7):A498.

16. Roland M, Torgerson DJ. Understanding controlled trials: What are pragmatic trials? BMJ. 1998;316(7127):285.

17. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence — what is it and what can it tell us. N Engl J Med. 2016;375(23):2293–7.

18. Sugarman J, Califf RM. Ethics and regulatory complexities for pragmatic clinical trials. JAMA. 2014;311(23):2381–2.

19. US Food and Drug Administration. Framework for FDA’s real-world evidence program. December 2018. 2019.

20. Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM, eds. Developing a Protocol for Observational Comparative Effectiveness Research: A User’s Guide. AHRQ Publication No. 12(13) — EHC099. Rockville, MD: Agency for Healthcare Research and Quality, January 2013.

21. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Annals of internal medicine. 2007;147(8):573–7.


For citations:

Kolbin A.S., Belousov D.Yu. Chinese experience on using RWE to support drug research, development and evaluation. Real-World Data & Evidence. 2022;2(1):17-27. (In Russ.)

Views: 189

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2782-3784 (Online)